LEAPFROG
LIVE

Serial Number

79353163

Owner

Leapfrog Remedies Ltd

Attorney

Miriam D. Trudell

Filing Date

Jul 6, 2022

Add to watchlist:

No watchlists yet
View on USPTO

LEAPFROG Trademark

Serial Number: 79353163 • Registration: 7357663

LEAPFROG is a trademark filed by Leapfrog Remedies Ltd on July 6, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Leapfrog Remedies Ltd

16 Southside Quarter,

Entity Type: 99

Trademark Details

Filing Date

July 6, 2022

Registration Date

April 16, 2024

Published for Opposition

January 30, 2024

Goods & Services

Pharmaceuticals for the prevention and treatment of iron disorders, allergies, skin disorders, immune system related diseases and disorders; Pharmaceuticals preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, herpetological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders in domestic animals; Antibacterial preparations for human absorption and consumption, namely, antibacterial pharmaceuticals, antibacterial spray, antibacterial substance for medical purposes, antibacterial hand lotions; antibiotic preparations; antiviral and anti-infectious preparations, namely, antivirals, pharmaceutical products for the treatment of infectious diseases or viral infections; anti-inflammatory preparations; pharmaceutical preparations for dermatological uses; medicinal preparations for slimming purposes; antiseptics, disinfectants; diagnostic preparations for medical purposes; natural remedies in the nature of preparations for the treatment of gastrointestinal conditions, hormonal and chemical imbalance, immune system related diseases and disorders, sleep disorders; herbal tinctures for medical purposes; herbal health preparations and remedies, namely, herbal supplements, remedies in the form of chewable tablets, for boosting energy, boosting immune system, promoting healthy skin; cough remedies, namely, cough syrups, cough lozenges, cough treatment preparations; remedies for colds, namely, preparations for treating colds; pharmaceutical preparations derived from natural substances for remedial purposes, namely, for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, herpetological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; nasal sprays for medical purposes, nasal rinse, nasal drops for treatment of allergies, nasal decongestants; allopathic remedies, namely, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; homeopathic remedies, namely, homeopathic supplements, homeopathic pharmaceuticals for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genito-urinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; herbal tea preparations for medicinal use; herbal oils being herbal extracts adapted for medical use, herbs for medicinal uses; roots for medicinal purposes; peels for medicinal purposes in the nature of medicated skin care preparations; medicated hair lotions and shampoos; medicated skin care lotions and creams; dietary and nutritional supplements for human beings; mineral nutritional supplements; vitamin supplements; dietetic substances, namely, preparations, chews, tablets adapted for medical use; food for babies and infants; infant formula; dietary fibre for treating constipation, aiding digestion; protein powder dietary supplements; medical plasters

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Jul 25, 2025 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 15, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Nov 15, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 15, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 15, 2024 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 9, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 19, 2024 FICS
FINAL DISPOSITION PROCESSED
Oct 19, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 17, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 16, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 16, 2024 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 8, 2024 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 20, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 20, 2024 OPNR
NOTIFICATION PROCESSED BY IB
Jan 30, 2024 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 30, 2024 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 10, 2024 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 10, 2024 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 22, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 9, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 8, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 8, 2023 TROA
REFUSAL PROCESSED BY IB
Jul 4, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 9, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jun 9, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 26, 2023 RFCR
NON-FINAL ACTION WRITTEN
Apr 25, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 20, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 4, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 31, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Oct 27, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 20, 2022 REPR